Arndt Vogel reports real-world tumor whole-genome sequencing yields actionable biomarkers in most patients and leads to clinical consequences for many, supporting broader NGS adoption despite reimbursement gaps.
Real-world clinical utility of tumor whole genome sequencing in solid cancers
actionable biomarkers in 73% of pts (27% for reimbursed and 63% for experimental💊
clinical consequences for 41% of tested pts
NGS is key today
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare